Interferon‑γ (IFN‑γ)
What it is:
Interferon‑γ is a naturally occurring cytokine that plays a key role in the immune response. In medicine it is manufactured in the lab (recombinant human IFN‑γ) and sold as a prescription drug (brand names : Rebetol®, Actimmune®, etc.). The drug is used in a few very specific medical situations, most commonly for certain immune‑deficiency disorders.
1. How it works (Mechanism of Action)
- Activates macrophages – boosts their ability to phagocytose (engulf) and kill bacteria, fungi, and parasites.
- Promotes antigen presentation – enhances the ability of immune cells to show foreign particles to T‑cells.
- Stimulates cytokine production – drives a Th1‑type immune response that is especially useful against intracellular pathogens.
Because of these effects, IFN‑γ is a targeted “immune‑boost” therapy rather than a broad‑spectrum antimicrobial.
2. Approved Indications (US FDA & EMA)
| Condition |
Why IFN‑γ helps |
Typical regimen |
| Chronic Granulomatous Disease (CGD) |
CGD patients lack a functional respiratory burst in neutrophils/macrophages. IFN‑γ “rescues” part of this pathway. |
10–20 µg/kg by subcutaneous injection, 3–5 × week‑1, then 3 × week‑2. |
| Disseminated Mycobacterium avium complex (MAC) in CGD |
Same reason – boosts macrophage killing of mycobacteria. |
Same as above. |
| Chronic granulomatous disease (CGD) – prophylaxis of infections |
Regular dosing reduces serious infections. |
See above. |
| Chronic granulomatous disease – treatment of infections |
Same as above. |
See above. |
(Outside of these indications, IFN‑γ is not FDA‑approved for general infection control or “immune‑boosting.”)
3. Dosing & Administration
| Patient type |
Dose |
Frequency |
Route |
| Children (1‑16 y) |
10–20 µg/kg |
3 × week‑1, 3 × week‑2 |
Subcutaneous |
| Adults (>16 y) |
10–20 µg/kg |
3 × week‑1, 3 × week‑2 |
Subcutaneous |
| Maintenance |
10–20 µg/kg |
3 × week‑1, 3 × week‑2 |
Subcutaneous |
- Subcutaneous injection into the thigh, abdomen, or upper arm.
- Do NOT inject into the same site for >2 weeks; rotate sites to avoid lipodystrophy.
- Needle size: 25‑27 g, 1‑1.5 in long.
Note: Dosing is highly individualized; your clinician will adjust based on weight, age, response, and side‑effect profile.
4. Common Side Effects
| System |
Typical symptom |
How to manage |
| Injection site |
Pain, redness, swelling, induration |
Massage, warm compress, change site |
| Flu‑like |
Fever, chills, myalgia, fatigue |
NSAIDs (ibuprofen, naproxen) for mild symptoms; rest |
| Hematologic |
Transient leukopenia, anemia, thrombocytopenia |
CBC monitoring; pause dose if counts drop >3 × 10⁹/L |
| Gastrointestinal |
Nausea, vomiting |
Take with food, antiemetics |
| Psychological |
Depression, anxiety, irritability |
Discuss with clinician; consider counseling |
| Liver |
Mild transaminase elevations |
Monitor LFTs every 2–4 weeks |
| Rare |
Anaphylaxis, severe hypersensitivity |
Seek immediate care if severe reaction |
5. Contraindications & Precautions
| Category |
Key points |
| Pregnancy |
Category D. Limited data. Avoid unless no alternative. |
| Breastfeeding |
Limited data; likely excreted into milk. Discuss with clinician. |
| Autoimmune disease |
May exacerbate conditions (e.g., rheumatoid arthritis, lupus). |
| Active malignancy |
Immunostimulation could theoretically promote tumor growth. |
| Severe infections |
Use only when benefits outweigh infection risk. |
| Severe liver disease |
Monitor LFTs; dose may need adjustment. |
| History of hypersensitivity to interferon |
Avoid. |
6. Drug‑Drug Interactions
- Antacids (aluminum, magnesium) – may reduce absorption if given within 30 min of injection.
- Immunosuppressants (cyclosporine, tacrolimus) – IFN‑γ can antagonize their action; monitor drug levels.
- Anti‑TNF agents – possible additive immune modulation; monitor closely.
- Vaccines (live vaccines) – IFN‑γ can alter response; avoid live vaccines while on therapy.
Always inform your prescriber about all medications, supplements, and herbal products.
7. Patient & Caregiver Tips
- Injection technique: Use a new sterile needle each time. Rotate sites: thighs → abdomen → upper arm.
- Cold pack: Apply after injection to reduce pain.
- Record a log: Date, time, dose, site, any symptoms.
- Watch for flu‑like symptoms: Report persistent high fever (>38.5 °C) or severe chills.
- Keep follow‑up appointments: CBC, LFTs, and infection screening every 4–6 weeks.
- Mental health: Discuss mood changes with your provider.
- Keep injection kit refrigerated (2–8 °C) before use. Thaw at room temperature for 30 min.
- Avoid alcohol: May exacerbate liver side effects.
8. When to Call Your Doctor
- Persistent fever >3 days or chills >38.5 °C.
- Severe injection site reaction (pain, swelling >2 cm).
- Sudden worsening of fatigue, mood changes, or confusion.
- Unexplained bruising or bleeding (possible thrombocytopenia).
- Yellowing of skin/eyes (liver dysfunction).
9. Key Take‑aways
- IFN‑γ is a targeted immune‑boosting biologic, not a general antibiotic.
- Its use is limited to very specific conditions—primarily chronic granulomatous disease.
- Dosing is weight‑based and usually given 3 × week‑1, 3 × week‑2.
- Side effects are often mild but can be flu‑like; monitor CBC and LFTs.
- Always coordinate care with a specialist familiar with IFN‑γ therapy.
Further Reading & Resources
- FDA Label for Rebetol® (US) – provides full prescribing information.
- American Academy of Allergy, Asthma & Immunology – guidelines on CGD management.
- National Institutes of Health (NIH) – National Institute of Allergy and Infectious Diseases – updates on immunotherapy.
Disclaimer: This information is for educational purposes and is not a substitute for professional medical advice. Always consult your healthcare provider for individualized guidance.